RPG Investment Advisory LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 102,014 shares of the biopharmaceutical company’s stock after buying an additional 23,436 shares during the period. Gilead Sciences makes up 1.7% of RPG Investment Advisory LLC’s investment portfolio, making the stock its 13th biggest position. RPG Investment Advisory LLC’s holdings in Gilead Sciences were worth $7,876,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. Northwest Bancshares Inc. raised its stake in Gilead Sciences by 8.9% during the third quarter. Northwest Bancshares Inc. now owns 28,816 shares of the biopharmaceutical company’s stock worth $2,224,000 after buying an additional 2,344 shares during the last quarter. Meeder Asset Management Inc. raised its stake in Gilead Sciences by 6.2% during the third quarter. Meeder Asset Management Inc. now owns 100,070 shares of the biopharmaceutical company’s stock worth $7,726,000 after buying an additional 5,841 shares during the last quarter. Swedbank raised its stake in Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after buying an additional 1,988,987 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in Gilead Sciences by 646.6% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 4,069 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 3,524 shares during the last quarter. Finally, Beaumont Financial Partners LLC bought a new position in Gilead Sciences during the third quarter worth $319,000. Hedge funds and other institutional investors own 78.09% of the company’s stock.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total value of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 150,000 shares of company stock valued at $11,087,500. Insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The firm had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the previous year, the firm posted $2.27 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.20%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.
A number of brokerages recently weighed in on GILD. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 20th. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 31st. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. Zacks Investment Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Finally, Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $87.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, October 26th. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $87.84.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by RPG Investment Advisory LLC” was published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2018/11/10/gilead-sciences-inc-gild-shares-bought-by-rpg-investment-advisory-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Stock Symbol
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.